By partnering with Numbers Protocol, AscendEX advances the transparency of data on its trading platform, making it verifiable across various networks.By partnering with Numbers Protocol, AscendEX advances the transparency of data on its trading platform, making it verifiable across various networks.

AscendEX Integrates Numbers Protocol’s Authentication System to Make Crypto Assets, Digital Data Verifiable, Traceable, And Secure

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
purple-blockchain-nodes

AscendEX, a global crypto trading platform that provides users with a wide variety of product suites, today announced a strategic collaboration with Numbers Protocol, a blockchain network designed to verify the authenticity of digital content, aiming to make it transparent. The partnership enabled the integration of AscendEX’s data network into Numbers Protocol’s innovative verification framework to strengthen AscendEX’s network security, transparency, and trust in the platform’s digital content and data applications.

Launched in 2018 by Wall Street investors, AscendEX is a global cryptocurrency exchange that enables retail customers and institutional clients to easily invest, trade, and earn crypto. By offering a wide variety of spot, margin, and futures trading products, wallet services, and staking support across multiple blockchain networks, AscendEX makes it seamless for people to buy, sell, swap, and earn on their crypto assets.

AscendEX Enchaining Data Verification Using Numbers Protocol’s Technology

The partnership highlights the importance of data verification and digital provenance. As the crypto market continues to evolve swiftly, so does the sophistication of bad actors seeking to exploit vulnerabilities. Fraudsters often take advantage of weaknesses in decentralized networks, gaps in the customer onboarding process, and compliance to manipulate cryptocurrency platforms.

Crypto platforms are vulnerable to advanced fraud risks (like phishing schemes, account takeovers, pump-and-dump schemes using fake customer accounts, identity fraud using AI-produced IDs, money laundering using unverified wallets, and exploitation of KYC gaps during customer onboarding) because of the pseudonymity of blockchain technology. For crypto exchanges, Web3 applications, DeFi platforms, and wallets, data verification has become a crucial tool for preventing fraud activities and enabling compliance with regulatory standards.

Numbers Protocol has positioned itself as a solution to these problems. By running decentralized technologies and its specialized blockchain network, Numbers Protocol creates immutable records of data/digital content, making them verifiable and traceable across various chains.

Through the partnership above, AscendEX leverages Numbers Protocol’s digital provenance framework to securely track the authenticity of data on its trading platform. This cutting-edge approach enables AscendEX to prevent unauthorized movement of data across its platform and prevent data breaches, which helps ensure the legitimacy of digital content throughout its lifecycle on its network. Furthermore, through this alliance, AscendEX utilizes Numbers Protocol’s verification tools to verify data both with and without C2PA labels to ascertain the origin and authentication of crypto assets.

Unlocking The Power of Web3 with Data Traceability

The partnership with Numbers Protocol enables AscendEX to advance data traceability on its crypto trading network and unlock the full capability of DeFi on the platform. The move marks an important step toward creating a more transparent and verifiable DeFi data space. By combining AscendEX’s data trading network with Numbers Protocol’s provenance-focused authenticity framework, the two platforms are redefining the way Web3 developers and users can confidently engage with data they know to be secure and trustworthy.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09